ARTA
TPST icon

A.R.T. Advisors’s Tempest Therapeutics TPST Stock Holding History

A.R.T. Advisors’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13
Closed -$51K – 1761
2017
Q4 		$51K Sell
13
-10
-43% -$42K ﹤0.01% 1295
2017
Q3 		$96K Buy
23
+5
+28% +$21.4K ﹤0.01% 1213
2017
Q2 		$82K Sell
18
-12
-40% -$50.8K ﹤0.01% 1271
2017
Q1 		$161K Buy
+30
New +$140K 0.01% 1206
2016
Q3 		– Sell
-12
Closed -$176K – 1144
2016
Q2 		$176K Buy
12
+7
+140% +$160K 0.01% 1134
2016
Q1 		$143K Sell
5
-40
-89% -$845K 0.01% 1222
2015
Q4 		$1.29M Buy
+45
New +$1.48M 0.06% 458
2015
Q2 		– Sell
-10
Closed -$975K – 1720
2015
Q1 		$975K Sell
10
-9
-47% -$1.2M 0.03% 666
2014
Q4 		$2.41M Buy
19
+15
+375% +$1.1M 0.09% 323
2014
Q3 		$192K Buy
+4
New +$140K 0.01% 1114

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

A.R.T. Advisors's TPST Position: Q1 2018 in Review

A.R.T. Advisors sold out of Tempest Therapeutics (TPST) in Q1 2018, closing a stake of 13 shares — an estimated $51K sold.

A.R.T. Advisors first reported a position in TPST in Q3 2014 and held it in 10 quarters. The position peaked at $2.41M in Q4 2014. 41 funds tracked by Wall St. Rank hold TPST as of Q1 2018.

  • A.R.T. Advisors reported no remaining Tempest Therapeutics position as of Q1 2018 after selling out during the quarter.
  • A.R.T. Advisors sold 13 Tempest Therapeutics shares in Q1 2018, an estimated $51K.
  • A.R.T. Advisors first reported a position in Tempest Therapeutics in Q3 2014 and held it in 10 quarters.
  • A.R.T. Advisors's Tempest Therapeutics position peaked at $2.41M in Q4 2014.
  • 41 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2018.

Based on A.R.T. Advisors's 13F filing for Q1 2018, filed 15 May 2018.